Citigroup
MPLT

Citigroup’s MapLight Therapeutics MPLT Stock Holding History

Citigroup’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Buy
17,051
+16,091
+1,676% +$463K ﹤0.01% 3797
2026
Q1 		$19.5K Buy
960
+577
+151% +$10.3K ﹤0.01% 4828
2025
Q4 		$6.73K Buy
+383
New +$6.42K ﹤0.01% 5172

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's MPLT Position: Q2 2026 in Review

Citigroup increased its MapLight Therapeutics (MPLT) stake by 1,676% in Q2 2026, buying an estimated $463K and bringing the position to 17,051 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #3797.

Citigroup first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Citigroup held 17,051 shares of MapLight Therapeutics worth $611K as of Q2 2026.
  • Citigroup bought 16,091 MapLight Therapeutics shares in Q2 2026, an estimated $463K.
  • MapLight Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3797 holding.
  • Citigroup first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.